Navigation Links
Amylin to Present Data Showing Investigational Metreleptin Treatment Led to Long-Term Improvements in Diabetes and Lipid Control in Patients with Lipodystrophy
Date:4/15/2011

ction of the BLA by the end of this year, which will complete the application. If approved, metreleptin would be the first therapy indicated specifically for the treatment of diabetes and high triglycerides in patients with lipodystrophy, and the first approved therapeutic use of metreleptin.

About Amylin Pharmaceuticals, Inc.

Amylin Pharmaceuticals is a biopharmaceutical company dedicated to improving lives of patients through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN® (pramlintide acetate) injection and BYETTA® (exenatide) injection. Amylin's research and development activities leverage the Company's expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is headquartered in San Diego, California. Further information on Amylin Pharmaceuticals is available at www.amylin.com.

This press release contains forward-looking statements about Amylin which involve risks and uncertainties.  The actual results for Amylin could differ materially from those discussed due to a number of risks and uncertainties, including that the CMC section of the metreleptin BLA mentioned in this press release may not be submitted in a timely fashion, the estimate of the number of lipodystrophy patients mentioned in this press release may not be accurate, clinical trials or studies may not start when planned, confirm previous results, be predictive of real world use or achieve intended clinical endpoints; preclinical studies may not be predictive; our product candidates, including the product candidate mentioned in this press release, may not receive regulatory approval; and inherent scientific, regulatory and other risks in the drug development and commercialization process. These and additional risks and uncertainties are described more fully in Amyli
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Amylin Pharmaceuticals Initiates Phase 2B Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment in Obesity
2. Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society
3. Amylin and Lilly Announce Plans to Develop Pen Device for Exenatide Once Weekly
4. Amylin Pharmaceuticals Highlights New Data Supporting Therapeutic Potential of Obesity Pipeline at Obesity 2009
5. Amylin Pharmaceuticals Reports Third Quarter Financial Results
6. Amylin Pharmaceuticals and Eli Lilly and Company Statement on FDAs BYETTA(R) (Exenatide) Injection Update
7. Amylin Pharmaceuticals to Present at the 18th Annual Credit Suisse Healthcare Conference
8. Amylin Pharmaceuticals to Webcast Year-End Financial Results
9. Amylin Highlights 2010 Corporate Priorities at J.P. Morgan Healthcare Conference
10. Amylin and Takeda Announce Decision to Advance Development of Pramlintide/Metreleptin Combination Treatment for Obesity
11. Amylin Pharmaceuticals to Present at The Barclays Capital 2010 Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2014)... 2014 The global high content screening market ... ,Threat of Obsolescence, wherein technologies as well as their ... biotechnology companies as well as academic and government institutes ... a powerful research tool in drug discovery. The high ... the high content screening market. In high content screening, ...
(Date:10/1/2014)... 2014  Abaxis, Inc. (NasdaqGS: ABAX ), ... for the medical, research, and veterinary markets worldwide and ... markets in the United States , ... agreement with Patterson Veterinary Supply. Patterson ... of Abaxis veterinary products throughout the United ...
(Date:10/1/2014)... BOSTON , Oct. 1, 2014   ... market-leading provider of Anesthesia Information Management Systems (AIMS), ... Systems, LLC , a wholly owned subsidiary of ... healthcare information systems and connectivity solutions.  ... http://photos.prnewswire.com/prnh/20140930/149407 This partnership ...
Breaking Medicine Technology:High Content Screening Market by Instruments (Cell Imaging and Analysis System), by Applications (Primary and Secondary Screening, Target Identification and Validation, Toxicity Studies, Compound Profiling), Software & Services - Global Forecasts to 2High Content Screening Market by Instruments (Cell Imaging and Analysis System), by Applications (Primary and Secondary Screening, Target Identification and Validation, Toxicity Studies, Compound Profiling), Software & Services - Global Forecasts to 3Abaxis Announces Distribution Agreement with Patterson Veterinary Supply 2Abaxis Announces Distribution Agreement with Patterson Veterinary Supply 3Abaxis Announces Distribution Agreement with Patterson Veterinary Supply 4Plexus IS' Anesthesia Documentation Solution Strengthens NextGen Healthcare Product Offering 2Plexus IS' Anesthesia Documentation Solution Strengthens NextGen Healthcare Product Offering 3
... , , , LIBERTYVILLE, Ill., ... today that the Office of Orphan Products Development of the Food ... for the treatment of Spinal Muscular Atrophy. , , ... for Spinal Muscular Atrophy has ever reached the important stage of ...
... , , , ... Forest Laboratories today announced that results of four phase III ... The Lancet showing that roflumilast, a phosphodiesterase 4 ... to severe COPD. , , COPD is ...
Cached Medicine Technology:Families of Spinal Muscular Atrophy Receives FDA Orphan Drug Designation For Quinazoline495 For The Treatment of Spinal Muscular Atrophy 2Families of Spinal Muscular Atrophy Receives FDA Orphan Drug Designation For Quinazoline495 For The Treatment of Spinal Muscular Atrophy 3Families of Spinal Muscular Atrophy Receives FDA Orphan Drug Designation For Quinazoline495 For The Treatment of Spinal Muscular Atrophy 4Four Studies Published in The Lancet Show roflumilast (Daxas(R)), a New Oral Approach to COPD, Improves Lung Function and Reduces Exacerbations 2Four Studies Published in The Lancet Show roflumilast (Daxas(R)), a New Oral Approach to COPD, Improves Lung Function and Reduces Exacerbations 3Four Studies Published in The Lancet Show roflumilast (Daxas(R)), a New Oral Approach to COPD, Improves Lung Function and Reduces Exacerbations 4Four Studies Published in The Lancet Show roflumilast (Daxas(R)), a New Oral Approach to COPD, Improves Lung Function and Reduces Exacerbations 5Four Studies Published in The Lancet Show roflumilast (Daxas(R)), a New Oral Approach to COPD, Improves Lung Function and Reduces Exacerbations 6Four Studies Published in The Lancet Show roflumilast (Daxas(R)), a New Oral Approach to COPD, Improves Lung Function and Reduces Exacerbations 7Four Studies Published in The Lancet Show roflumilast (Daxas(R)), a New Oral Approach to COPD, Improves Lung Function and Reduces Exacerbations 8Four Studies Published in The Lancet Show roflumilast (Daxas(R)), a New Oral Approach to COPD, Improves Lung Function and Reduces Exacerbations 9
(Date:10/2/2014)... HealthDay Reporter WEDNESDAY, ... out all the stops to rescue surgical patients in ... cost of such heroism is questionable, a new study ... better at saving elderly patients with life-threatening complications after ... intensity, said senior author Dr. Amir Ghaferi. He is ...
(Date:10/1/2014)... beta-amyloid is strongly associated with Alzheimer,s disease; however, researchers ... is the causal agent of the onset and development ... is that beta-amyloid is not harmful when found in ... it self-assembles to form the so-called amyloid fibrils , ... alone, but with multiple ones because each aggregate of ...
(Date:10/1/2014)... Physical Sciences Research Council (EPSRC) will focus on ... systems which run, for example, manufacturing plants, power ... , The research will help understand and ... systems behind our critical national infrastructure. , ... (RITICS), based at Imperial College London, is co-ordinating ...
(Date:10/1/2014)... 01, 2014 Familylifeinsurancequotes.org has released ... insurance for senior citizens. , Senior citizens can ... now sell coverage to seniors who are over 50 ... purchased without taking a medical examination. , Term life ... and senior clients can qualify. Having life insurance during ...
(Date:10/1/2014)... 2014 Lifeinsurance-policy.com has released a ... life insurance prices for smokers. , Smoking will always ... Comparing quotes is the best method to find affordable ... customers who need coverage. , Whole life insurance ... the policy. Since the coverage is permanent, the initial ...
Breaking Medicine News(10 mins):Health News:'High-Intensity' Hospitals Save More Elderly After Surgery: Study 2Health News:'High-Intensity' Hospitals Save More Elderly After Surgery: Study 3Health News:Laying siege to beta-amyloid, the key protein in Alzheimer's disease 2Health News:£2.5 million to recognize and reduce cyber-attack threats to critical infrastructure 2Health News:Affordable Term Life Insurance - Senior Citizens Can Qualify for Coverage! 2Health News:Affordable Whole Life Insurance Premiums for Smokers! 2
... internet about human incidence of bird flu in Quebec is ... ,Dr Patrick Dolce, the man at the helm ... "Everything is false; there is no patient, no nothing." ... devoted to avian flu which had enabled a report of ...
... C last week. Public health department in Toronto has alerted ... contagious and the man who died happened to have frequented ... ,Although only a single case has been notified, owing to ... public to be cautious.,Meningitis C is a contagious disease caused ...
... about memory could offer an early warning system for ... at Rush University Medical Center. The researchers have found// ... changes in the brain related to Alzheimer's disease. Their ... Neurology. ,The researchers looked at the association ...
... for termination of early pregnancies, might be helpful to ... from the University of California, whose work has been ... licensed drug that blocks the hormone progesterone. In pregnancy, ... If it is depleted the developing fetus can get ...
... and colleagues at four other medical centers have launched ... may contribute to early atherosclerosis. ,“If we can ... who have a genetic predisposition to develop atherosclerosis, we ... stroke sooner and more aggressively,” said David Herrington, M.D., ...
... an imbalance in the overall treatment has lead to the ... of effective dietary care are met with. ,According ... not yet analyzed the nutritional value of the diets the ... any miscalculation in their prescription of menus can lead to ...
Cached Medicine News:Health News:Memory Complaints Are Associated With Alzheimer's Disease 2Health News:Memory Complaints Are Associated With Alzheimer's Disease 3Health News:Breast Cancer Prevention Using Abortion Drug Considered 2Health News:Study Underway to Identify Genes Contributing to Heart Attack Risk 2Health News:Hospital Food Needs Improvement to Meet the Nutritional Needs of the Patient 2
2 mm wide curved tip. Round handle....
3 mm disposable Lance blade. Can fit in to the N0521 Storz handle....
Consist of 6 disposable bevel blades (N0522) and chuck handle (0521). Malleable shafts. Designated most popular model or size....
1.5 mm x 12 mm tip. Angled 15 degrees. Teflon coated with diathermy attachment....
Medicine Products: